Drug Detail

Information about Imatinib + Ipilimumab

Generic Name	Imatinib + Ipilimumab
IND	Imatinib + Ipilimumab
Brand Name (US)
Manufacturer	Novartis + Bristol Myers-Squibb
Drug Type	Tyrosine Kinase Inhibitor and Monoclonal antibody
Delivery	Oral + Intravenous
Approval Status	Both are approved. This combination is not approved for GIST. It is being evaluated in a phase 1 trial for GIST.
Indications
Overall Strategy	KIT Protein and immune system
Strategy	Block KIT + Stimulate the immune system
Drug Category	KIT/PDGFRA inhibitor + CTLA4 inhibitor

Links
Trials of this drug
	Ipilimumab and Imatinib Mesylate in Advanced Cancer

Trial results